Dr. Edgardo Santos

  • MD
  • Medical Oncologist
  • Spoken languages English


Dr. Edgardo Santos (FACP) is a Medical Oncologist with Florida Precision Oncology and specializes in thoracic oncology and head and neck cancer. Dr. Santos previously served as the Medical Director of Cancer Research at the Lynn Cancer Institute at Boca Raton Regional Hospital. He is also a Clinical Affiliate Associate Professor at the Charles E. Schmidt College of Medicine at Florida Atlantic University. He is a former recipient of the American Cancer Society Spirit Award and is actually a Board Member/Chair of the Program Committee at Florida American Society of Clinical Oncology (FLASCO) and the Chair of the Publication Committee of the International Association of the Study of Lung Cancer (IASCL). Dr. Santos also serves as the Co-Chair of the IASLC Latin American Group and founder member of the Oncology Latin America Association (OLA).

Career Positions

Current position(s)

  • Florida Precision Oncology - Medical Oncologist, Aventura, FL

Past position(s)

  • Lynn Cancer Institute - Medical Director of Cancer Research, Boca Raton, FL



  • University of Panama School of Medicine, MD, Medicine, Panama, Panama


  • Jackson Memorial Medical Center, MD, Internal Medicine, Miami, FL


  • University of Miami/Sylvester Comprehensive Cancer Center, Hematology/Medical Oncology, Miami, FL


Awards and honors

  • The Global Directory of Who’s WhoSpirit Award of the American Cancer Society

Clinical studies

Primary Objective • To assess whether ALK kinase domain mutations (G1202/C1156Y /I1171/L1196/ V1180/ F1174/ compound mutation) associated with drug resistance are prognostic for objective response to subsequent ALK inhibitor therapy. • To assess whether subsequent pemetrexed based chemotherapy improves objective response comparing to ALK inhibitor therapy for no ALK mutation patients • To evaluate objective responses of patients with specific genetic alterations (ALKL1198F/MET double mutation or high-level MET gene amplification) treated with crizotinib.

View Study